Age Factor Influencing On Patients Subjected To Coronary Artery Bypass Grafting

Abdurakhmanov, Z.M.

doi:10.24966/avs-7397/100038

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Approximately 7% among all leading causes of the overall morbidity in Uzbekistan attributed to chronic heart failure [1]. As known, over the last 20 years the rate of morbidity and mortality is diminished in patients with heart failure with reduced ejection fraction (HFrEF) by means of medications targeted the renin-angiotensin-aldosterone system [2,3]. As previously reported, several efforts to potentially benefit patients with HFrEF due to the rise of the activity of natriuretic peptides (NPs) have failed until a large (n=8442 patients), phase III, randomized, controlled clinical trial (PARADIGM-HF) which highlighted the advantageous results of sacubitril/valsartan regarding decrease the risk of cardiovascular death and hospitalization for heart failure by 20% and 16% less risk for death from any cause as compared with enalapril (p<0,001) [4].…”

Section: Introductionmentioning

confidence: 99%

Effective influence of sacubutril/valsartan on systolic function of left ventricle in patients with heart failure and a reduced ejеction fraction

Adilova¹,

Akbarova²

2021

ОИ

View full text Add to dashboard Cite

Aim: We evaluated the influence of sacubitril/valsartan on the left ventricle function and clinical status of patients with heart failure and a reduced ejection fraction. Materials and methods: From 2018 to 2020, patients cured with 50-200 mg sacubitril/valsartan after coronary bypass grafting or coronary stenting for ischemic heart disease and HFrEF (aged 54-70 years) were enrolled in this prospective study. Results: There was no death case. There was a female prevalence with female to male ratio of 1,7:1. the value of ejection fraction high significantly increased (p=0,035), whereas the indices of left ventricle end-diastolic volume (p=0,015) and end-diastolic volume index (p=0,022) as well as left ventricle mass index were high significantly decreased (p=0,001) that indicate the amelioration of left ventricle systolic function. Correspondingly, the clinical status of all patients improved according to New York Heart Association Class (p=0,001). Conclusion: The post-CABG or PCI patients with HFrEF should be cured with sacubitril/valsartan basing on its implementation instruction. Nevertheless, future studies should focus on a larger cohort of post-CABG or PCI patients to compare the effectiveness and safety of sacubitril/valsartan usage raising from its adverse event in comparison to conventional therapy.

show abstract

Section: Introductionmentioning

confidence: 99%